Latest 10-Q quarterly reports

Mereo BioPharma reports a narrower net loss for Q1 2026 compared to the prior year, driven by lower administrative expenses and foreign currency gains, alongside increased R&D spending primarily on setrusumab.

OptimumBank Holdings, Inc. reports a strong first quarter for 2026 with significant growth in net income, driven by increased net interest income and noninterest income, alongside strategic expansion initiatives.

PMV Pharmaceuticals reports a net loss of $18.0 million for Q1 2026, with operating expenses decreasing but interest income also declining, while maintaining sufficient cash for the next 12 months.

CVRx, Inc. announced its first quarter 2026 financial results, showcasing a 20% increase in revenue driven by strong U.S. sales, while also reporting a slight reduction in net loss compared to the prior year period.

Coya Therapeutics reports a decrease in R&D expenses and an increase in G&A for Q1 2026, with cash reserves projected to last into the second half of 2027.

Xilio Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing increased collaboration revenue, higher R&D spending, and a strengthened cash position.

SAB Biotherapeutics details significant R&D investment and progress in its lead Type 1 Diabetes therapy, SAB-142, alongside a substantial capital raise.

Sagimet Biosciences reports a significant decrease in R&D expenses for Q1 2026, improved cash flow from investing activities, and sufficient liquidity for the next 12 months following a substantial capital raise.

Longduoduo Company Limited reported a significant decrease in revenue for the third quarter of fiscal year 2026, driven by economic headwinds and cautious consumer spending.

Achieve Life Sciences reported its first quarter 2026 financial results, highlighting a net loss of $10.2 million and a significant capital raise of $180 million, while also anticipating a delay in FDA approval for cytisinicline.

Prelude Therapeutics Inc. reported its first-quarter 2026 financial results, highlighting progress in its oncology pipeline and a significant cash position following a recent offering.

Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026, with increased operating expenses primarily in R&D and G&A, while maintaining a cash runway projected into 2028.

Olema Pharmaceuticals has entered into a lease agreement for a new corporate headquarters in South San Francisco, California.

Vestis Corporation reported a significant improvement in its second-quarter financial results, moving from a net loss to a net profit, driven by cost-saving measures and operational efficiencies.

C4 Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial performance, ongoing clinical trials, and strategic collaborations.

Ovid Therapeutics Inc. reported its first quarter 2026 financial results, highlighting increased research and development expenses and significant proceeds from private placements and warrant exercises.

Sleep Number Corporation reported a substantial net loss of $50.3 million for the first quarter of 2026, with significant concerns raised about its ability to continue as a going concern.

Via Transportation reported a 29% year-over-year revenue increase to $127.4 million for Q1 2026, though the company continued to post a net loss of $20.1 million.

Passage Bio's Q1 2026 Form 10-Q filing details ongoing clinical development, a significant workforce reduction, and the initiation of a strategic alternatives review, while highlighting substantial doubt about its going concern.

Neuraxis, Inc. announced its first quarter 2026 financial results, showcasing a significant 79.5% year-over-year increase in net sales driven by expanded insurance coverage for its IB-Stim device.

Ampco-Pittsburgh Corporation's Q1 2026 filing reveals a revenue increase driven by the Air and Liquid Processing segment, while the Forged and Cast Engineered Products segment saw a decline, alongside a net loss for the quarter.

Unicycive Therapeutics reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, despite a decrease in R&D spending.

Ducommun Incorporated announced a significant increase in net income for the first quarter of 2026, driven by higher revenues and improved gross profit margins.

Mammoth Energy Services reported a return to profitability in Q1 2026 with $5.2 million in net income, driven by strategic divestitures and increased utilization in its rental and drilling segments.

Better Home & Finance reported a net loss of $70.3 million for Q1 2026 as it continues to divest its U.K. banking operations.

SoundHound AI reports Q1 2026 revenue of $44.2 million, a 52% increase year-over-year, while navigating ongoing integration of recent acquisitions.

Traeger reported a net income of $2.9 million for Q1 2026, driven by cost-saving initiatives under Project Gravity and a significant tariff-related tax credit recovery.

Exodus Movement reported a net loss of $32.1 million for Q1 2026, driven by digital asset volatility and increased operating expenses.

Blue Acquisition Corp. reports Q1 2026 financial results while progressing toward its business combination with Blockfusion.

Camber Energy reports a net loss of $1.7 million for Q1 2026 amid ongoing going concern doubts and significant working capital deficiencies.